It is important to note that the quality of evidence supporting the use of ICIs for the treatment of brain tumors varies by tumor type, as the ICI treatment response of many brain tumors (including IDH-mut gliomas and several BM histologies) has yet to be reported with prospective, randomized clinical trials. Here, IDH1 is linked to brain neoplasm.